ACHE and Alzheimer disease: AChE inhibitors (AChEIs) are currently the first-line drugs for the symptomatic treatment of Alzheimer’s disease (AD), where AChEIs may sustain the cholinergic transmission in early to moderate AD stages (Mufson et al., 2008).